Fig. 1From: Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trialC3a, C5a, factor Bb, MASP-2, thromboxane A2, ADAMTS13 and IL-8. Mean predictions of the LMMs per group are plotted in the graphs. ADAMTS13 a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, BSC best supportive care, IL-8 interleukin-8, MASP-2 Mannan-binding lectin serine protease 2Back to article page